Abstract: Grape seed extract compositions and related systems and methods for manufacture are provided. The methods can include obtaining a grape seed extract source material; filtering the grape seed extract source material to obtain a first retentate and a first permeate; drying the first retentate to obtain a first grape seed extract having a first mean degree of polymerization; filtering the first permeate to obtain a second retentate and a second permeate; drying the second retentate to obtain a second grape seed extract having a second mean degree of polymerization less than the first mean degree of polymerization; purifying the second permeate to obtain a purified liquid; and drying the purified liquid to obtain a third grape seed extract having a third mean degree of polymerization less than the second mean degree of polymerization.

Abstract: Grape seed extract compositions and related methods for improving cognition using the same. The grape seed extract compositions may be produced by obtaining a grape seed extract source material; filtering the grape seed extract source material to obtain a first retentate and a first permeate; drying the first retentate to obtain a first grape seed extract having a first mean degree of polymerization; filtering the first permeate to obtain a second retentate and a second permeate; drying the second retentate to obtain a second grape seed extract having a second mean degree of polymerization less than the first mean degree of polymerization; purifying the second permeate to obtain a purified liquid; and drying the purified liquid to obtain a third grape seed extract having a third mean degree of polymerization less than the second mean degree of polymerization; and combining the first, second, or third grape seed extracts.

Abstract: The present disclosure relates to methods for extracting pomegranate to obtain pomegranate compositions. The present disclosure is further directed to foods and beverages containing pomegranate compositions obtained by the methods.

Abstract: Grape seed extract compositions and related systems and methods for manufacture are provided. The methods can include obtaining a grape seed extract source material; filtering the grape seed extract source material to obtain a first retentate and a first permeate; drying the first retentate to obtain a first grape seed extract having a first mean degree of polymerization; filtering the first permeate to obtain a second retentate and a second permeate; drying the second retentate to obtain a second grape seed extract having a second mean degree of polymerization less than the first mean degree of polymerization; purifying the second permeate to obtain a purified liquid; and drying the purified liquid to obtain a third grape seed extract having a third mean degree of polymerization less than the second mean degree of polymerization.

Abstract: In general, the subject matter described herein relates to dry cannabinoid emulsions (DCEs), dried cannabinoid complexes, and related systems and methods. An example method of forming a DCE includes: obtaining a water phase; obtaining an oil phase including a cannabinoid; forming an oil-in-water emulsion in which the oil phase is suspended as particles in the water phase; and drying the emulsion in a refractance window dryer. An example method of forming a dried cannabinoid-cyclodextrin complex includes: obtaining an aqueous solution including cyclodextrin; adding a mixture of ethanol and a cannabinoid to the aqueous solution to form a cannabinoid-cyclodextrin complex; and drying the cannabinoid-cyclodextrin complex in a refractance window dryer.

Abstract: The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing A-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and/or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and/or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional NO modulating agent and/or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent.

Abstract: The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing A-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and/or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and/or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional NO modulating agent and/or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent.

Abstract: The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing A-type procyanidins, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease and/or vascular circulation disorders, prevent or reduce the risk of heart attack, stroke, congestive heart failure and/or kidney failure, or to improve blood flow, for example renal blood flow. The composition may optionally contain an additional NO modulating agent and/or a cardiovascular-protective or therapeutic agent, or may be administered in combination with such an agent.

Abstract: The invention relates to compositions, and methods of use thereof, containing polyphenols such as flavanols, procyanidins, their derivatives and epimers thereof, for improving vascular circulation in peripheral and/or small blood vessels.

Abstract: A process is described for selectively extracting cocoa procyanidins from an aqueous mixture of cocoa polyphenols by using a particular sequence of solvents to extract selected procyanidin monomers and/or oligomers. The solvents are n-butyl acetate, ethyl acetate, methyl acetate, diethyl ether, or mixtures of methyl acetate and diethyl ether. Preferably, the aqueous mixture of cocoa polyphenols is first extracted with n-butyl acetate. The mixtures of methyl acetate and diethyl ether are between 25:75 and 75:25 (v/v).

Abstract: An improved process for separating and isolating individual polar protic monomer(s) and/or oligomer(s) on the basis of degree of polymerization. A liquid sample containing polar protic monomer(s) and/or oligomer(s) is introduced into a liquid chromatography (LC) column packed with a polar bonded stationary chromatographic phase. The individual polar protic monomer(s) and/or oligomer(s) are separated via a binary mobile phase elution. One or more individual fractions containing the monomer(s) and/or oligomer(s) are eluted. The polar protic monomer(s) and/or oligomer(s) may be proanthocyanidins, hydrolyzable tannins, oligosaccharides, oligonucleotides, peptides, acrylamides, polysorbates, polyketides, poloxarners, polyethylene glycols, polyoxyethylene alcohols or polyvinyl alcohols. The binary mobile phase comprises an A phase consisting essentially of a polar aprotic solvent and a B phase consisting essentially of a polar protic solvent. A process for separating and isolating xanthine(s) (e.g.

Abstract: A process is described for selectively extracting cocoa procyanidins from an aqueous mixture of cocoa polyphenols by using a particular sequence of solvents to extract selected procyanidin monomers and/or oligomers. The solvents are n-butyl acetate, ethyl acetate, methyl acetate, diethyl ether, or mixtures of methyl acetate and diethyl ether. Preferably, the aqueous mixture of cocoa polyphenols is first extracted with n-butyl acetate. The mixtures of methyl acetate and diethyl ether are between 25:75 and 75:25 (v/v).

Abstract: An improved process for separating and isolating individual polar protic monomer(s) and/or oligomer(s) on the basis of degree of polymerization. A liquid sample containing polar protic monomer(s) and/or oligomer(s) is introduced into a liquid chromatography (LC) column packed with a polar bonded stationary chromatographic phase. The individual polar protic monomer(s) and/or oligomer(s) are separated via a binary mobile phase elution. One or more individual fractions containing the monomer(s) and/or oligomer(s) are eluted. The polar protic monomer(s) and/or oligomer(s) may be proanthocyanidins, hydrolyzable tannins, oligosaccharides, oligonucleotides, peptides, acrylamides, polysorbates, polyketides, poloxamers, polyethylene glycols, polyoxyethylene alcohols or polyvinyl alcohols. The binary mobile phase comprises an A phase consisting essentially of a polar aprotic solvent and a B phase consisting essentially of a polar protic solvent. A process for separating and isolating xanthine(s) (e.g.

Abstract: A process is described for selectively extracting cocoa procyanidins from an aqueous mixture of cocoa polyphenols by using a particular sequence of solvents to extract selected procyanidin monomers and/or oligomers. The solvents are n-butyl acetate, ethyl acetate, methyl acetate, diethyl ether, or mixtures of methyl acetate and diethyl ether. Preferably, the aqueous mixture of cocoa polyphenols is first extracted with n-butyl acetate. The mixtures of methyl acetate and diethyl ether are between 25:75 and 75:25 (v/v).

Abstract: The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or for treatment of a disease or condition associated with damage to the hippocampus. The subject may be a human or a veterinary animal.